YOU ARE HERE:
Four more Ranbaxy drugs on WHO pre-qualification list
Ranbaxy Laboratories announced on 1st June that four more of its generic anti-HIV products have been included on the World Health Organization’s (WHO’s) list of prequalified medicines.
These four products - 600mg efavirenz tablets, 200mg efavirenz capsules, and 30 and 40mg d4T (stavudine) capsules - will now be available for organisations and countries in the developing world to buy at an affordable price.
Inclusion on the pre-qualification list means that the products are of good quality, safe and effective, and that their manufacturing sites comply with the WHO’s criteria.
Ranbaxy's chief executive officer and managing director, Malvinder Mohan Singh, said, “this is a significant development. We strongly feel that generic antiretrovirals are essential in the struggle against HIV / AIDS and are committed to providing high quality, cost-effective generics.”
Ranbaxy is an Indian company, which specialises in producing low-cost versions of drugs for sale in resource-limited countries. It now has twelve products on the pre-qualification list, as well as three antiretroviral products that have been approved by the United States Food and Drug Administration (FDA), making them eligible for purchase under the President's Emergency Plan for AIDS Relief (PEPFAR).
“Efavirenz is rapidly becoming a preferred drug in HIV treatment programmes in developing countries. The other newly listed drug, stavudine, is also being widely used as a first-line therapy against AIDS,” said Mr Singh. “Both products increase customer choice, enabling patients to access therapy easily, at affordable prices.”
The pre-qualification project was set up in 2001 by the WHO in collaboration with the Joint United Nations Programme on HIV / AIDS (UNAIDS), the United Nations Children's Fund (UNICEF), the United Nations Population Fund (UNFPA) and the World Bank. Its aim is to make the universal access to medicines easier by producing a list of medicines that meet standard levels of quality, safety and efficacy.
These four products - 600mg efavirenz tablets, 200mg efavirenz capsules, and 30 and 40mg d4T (stavudine) capsules - will now be available for organisations and countries in the developing world to buy at an affordable price.
Inclusion on the pre-qualification list means that the products are of good quality, safe and effective, and that their manufacturing sites comply with the WHO’s criteria.
Ranbaxy's chief executive officer and managing director, Malvinder Mohan Singh, said, “this is a significant development. We strongly feel that generic antiretrovirals are essential in the struggle against HIV / AIDS and are committed to providing high quality, cost-effective generics.”
Ranbaxy is an Indian company, which specialises in producing low-cost versions of drugs for sale in resource-limited countries. It now has twelve products on the pre-qualification list, as well as three antiretroviral products that have been approved by the United States Food and Drug Administration (FDA), making them eligible for purchase under the President's Emergency Plan for AIDS Relief (PEPFAR).
“Efavirenz is rapidly becoming a preferred drug in HIV treatment programmes in developing countries. The other newly listed drug, stavudine, is also being widely used as a first-line therapy against AIDS,” said Mr Singh. “Both products increase customer choice, enabling patients to access therapy easily, at affordable prices.”
The pre-qualification project was set up in 2001 by the WHO in collaboration with the Joint United Nations Programme on HIV / AIDS (UNAIDS), the United Nations Children's Fund (UNICEF), the United Nations Population Fund (UNFPA) and the World Bank. Its aim is to make the universal access to medicines easier by producing a list of medicines that meet standard levels of quality, safety and efficacy.
aidsmap resources
Africa news
- ‘Shocking’ rates of adverse events seen with traditional and medical circumcision in Kenya
- Poor results using non-medical HIV counsellors to screen for treatment eligibility in Malawi
- Belief in conspiracy theories means less HIV testing in South Africa
Asia and Pacific news
- Justice Edwin Cameron calls for a campaign against 'misguided criminal laws and prosecutions'
- Treatment outcomes in Latin America, China and Botswana: successes and shortfalls
- Lipodystrophy common, but does not affect adherence in Thai patients
Eastern Europe and Russia news
- Criminal HIV transmission and exposure laws spreading around the world ‘like a virus’
- Anti-HIV treatment provided to 3 million in poorer countries by end of 2007
- 2010 International AIDS Conference set for Vienna, with Eastern Europe focus
Latin America news
- Brazil rejects tenofovir patent
- Immigration and prevention: the effect of migration on risk behaviour
- Treatment outcomes in Latin America, China and Botswana: successes and shortfalls
Middle East news
- Justice Edwin Cameron calls for a campaign against 'misguided criminal laws and prosecutions'
- Half of all new HIV infections could be averted if proven prevention efforts expanded
- Roche agrees to temporary suspension of nelfinavir's (Viracept) European license - updated
